Pharmaceutical Trade Margin Rationalisation

Trade margin rationalisation is a drug-pricing method that limits the mark-up between the price charged by a pharmaceutical manufacturer to the trade and the price paid by the consumer. Instead of fixing only a medicine's final ceiling price, it caps the trade margin available across the distribution and retail chain.

How it works

The regulator identifies the price at which a manufacturer supplies a medicine to the first distributor or stockist, called the price to trade. It then limits the aggregate margin available between this price and the retail price, requiring the maximum retail price to be revised where the permitted margin is exceeded.

• Unlike a conventional ceiling price, this method primarily regulates the distribution-chain margin rather than directly determining the manufacturer's supply price.
• The margin may cover multiple intermediaries, including distributors, stockists and retailers.

Regulatory basis and application

Drug-price regulation operates through the Drugs (Prices Control) Order, 2013, issued under the Essential Commodities Act, 1955. The National Pharmaceutical Pricing Authority can implement rationalisation using the extraordinary public-interest power under paragraph 19 of the Order.

• In 2019, the NPPA applied this approach to selected non-scheduled anti-cancer medicines and capped the trade margin at 30 per cent of the price to trade.
• Scheduled formulations are ordinarily regulated through ceiling prices under the DPCO, whereas trade margin rationalisation can target excessive mark-ups in selected market segments.

Purpose and limitations

Rationalisation seeks to improve affordability while preserving reasonable incentives for pharmaceutical distribution. It is particularly relevant where high retail prices arise from large channel mark-ups rather than only from manufacturing costs.

• It can reduce retail prices without imposing an identical absolute price on every brand.
• Its effectiveness depends on the chosen base price and enforcement because controlling the margin alone does not necessarily control the manufacturer's underlying supply price.
• A sustainable policy must balance patient access, transparent pricing and the commercial viability of the supply chain.